Navigation Links
NAMS Journal Menopause Reflects on the WHI 10 Years Later
Date:5/30/2012

CLEVELAND, May 30, 2012 /PRNewswire/ -- A great deal has been learned in the decade since the first results from the Women's Health Initiative (WHI) were published on July 9, 2002. The WHI was the largest and longest trial of postmenopausal women using hormone therapy (HT). The 27,000 women were prescribed estrogen-alone therapy, estrogen-progestogen therapy, or a placebo for 5 to 7 years, respectively.

Researchers expected to find that hormones prevented chronic conditions of aging in women, including heart disease. Instead, they found that hormones produced a mix of risks and benefits. The subsequent data from the WHI suggest that the risks of HT vary with a woman's age (safer if started soon after menopause).

To commemorate the 10th anniversary of this landmark trial and its voluminous reporting, the June 2012 issue of Menopause will publish an editorial by JoAnn Manson, MD, DrPH, NCMP (NAMS President) and Lubna Pal, MBBS, MRCOG, MSc, NCMP, entitled "The Women's Health Initiative: An Unforgettable Decade," along with several other timely articles:

  • "Evolution of Postmenopausal Hormone Therapy Between 2002 and 2009" by Bruce Ettinger, MD, Sharon M. Wang, PharmD, MS, R. Scott Leslie, MPH, et al.
  • "A Decade of Postmenopausal Hormone Therapy Prescribing in the United States: Long-Term Effects of the WHI" by Amy Steinkellner, PharmD, Shannon Denison, MA, Sandra Eldridge, PharmD, et al.
  • "Hormone Therapy Prescribing Trends in the Decade After the Women's Health Initiative: How Patients and Providers Have Found a Way to Sleep Better at Night" by Jennifer Corbelli, MD, Rachel Hess, MD, MS (editorial)

These articles will be available on Menopause online on May 31, 2012, at 4 pm Eastern.

Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field—including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education—makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit our website: www.menopause.org


'/>"/>
SOURCE North American Menopause Society
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
2. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
3. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
4. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
5. Elsevier Launches New Journal: Journal of Applied Research in Memory and Cognition
6. Elsevier Launches New Journal: Journal of Obsessive-Compulsive and Related Disorders
7. Journal Article Suggests DermaClose® RC Used in Combination With VAC Therapy Can Dramatically Reduce the Need for Skin Grafting of Fasciotomy Wounds for Combat Related Trauma
8. New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses
9. Generex Subsidiary Antigen Express Announces Publication of Review Showcasing its Proprietary Therapeutic Vaccine Technology in the Journal Vaccine
10. Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys
11. Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Abdominal Aortic Aneurysm Repair Devices Market was ... 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The endovascular stent ... dominate the market during the study period. Continue Reading ... ... ...
(Date:3/24/2017)... 2017 New England Pediatric Device Consortium (NEPDC) ... including funding and in-kind service towards the commercialization of ... "Making blood draws less traumatic for children could ... experience better.  We,re looking forward to working with Velano ... care for the kids we treat," said Ann-Christine ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Wound ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 and ... Among the various wound care products type, the advanced wound ... 2015. Among the various applications, surgical wound segment held the largest share ...
Breaking Medicine Technology:
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... from third world countries to hospitals in the United States, it’s a threat ... on the current obstacles facing infection prevention and offers strategies for the healthcare ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
Breaking Medicine News(10 mins):